CLSN’s proprietary heat-activated liposome technology enables delivery of significantly higher concentrations of proven chemotherapy drugs directly to the tumor, which stops the progression of cancer and minimizes systemic toxicities. Liposomes are small membrane-enclosed sacks that can store or transport substances. CLSN’s heat-activated liposomes circulate within the tumor tissue. When heat is added locally, it causes the rapid release of the encapsulated chemotherapeutic agent directly within the targeted tumor. CLSN has completed animal studies that demonstrated intravenous administration of ThermoDox, in combination with targeted heat to the tumor, will produce doxorubicin drug concentrations in tumor tissue that are much greater than existing approved liposomal formulations of doxorubicin on the market today. The number of lives that could be saved each year from this breakthrough technology is in the tens of thousands.
CLSN also has a whole product pipeline of cancer drugs employing its heat activated liposomal technology including docetaxel and carboplatin. This technology improves efficacy and safety of anticancer agents. The approach CLSN takes provides a cost effective, low risk approval pathway. This technology will treat a broad range of cancers.
Time is our friend. The clinical is being done with participants who are very sick. I watched my mother-in-law die from liver cancer in 4 months. The 12 month PFS with RFA is attributable to some studies that were done to track patients with 3cm tumors not he 5-7cm we're dealing with. That's a 67% to 130% larger tumor and the trial seems to be going longer and longer which could, COULD, be giving a strong indication that TDOX works.